IMMUNOVANT, INC. — Income Charts
4 quarters of history · ending 2024-03-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$8M
R&D
$66M
D&A
$64K
Operating Income
—
EBITDA
$64K
Interest Expense
$8M
Interest Income
—
Other Income/Expense
—
Pretax Income
$-52M
Tax Provision
$232K
Net Income
$-51M
Net Margin
-575.6%
Effective Tax Rate
0.2%
DTA Valuation Allowance
$141M
ETR (Continuing Operations)
-0.2%
Operating Lease Cost
$300K
Revenue YoY Variation
140.8%
Revenue QoQ Variation
-6.2%
Income QoQ Variation
—